Top Markets
#1 Black Phoenix Black Phoenix +195.09%
#2 Islamic Coin Islamic Coin +158.04%
#3 Glidr Glidr +84.34%
#4 Gold Park Gold Park +36.39%
#5 Acurast Acurast +29.10%
#6 Cryptopia Cryptopia +21.79%
#7 BasedHype BasedHype +20.91%
#8 Quantum Resistant Ledger Quantum Resistant Ledger +17.30%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +16.57%
#10 Playnance Playnance +14.07%
Coin of the day
Black Phoenix Black Phoenix
Beállítások
Nyelv
MAGYAR
Pénznem
USD
Téma
VIA Pharmaceuticals, Inc. VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc.

VIAP
Helyezés a részvények között #41780
VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily... VIA Pharmaceuticals, Inc. is an emerging biotechnology company primarily focused on discovering and advancing therapeutic compounds for cardiovascular and metabolic disorders. The firm is building a portfolio of small-molecule drug candidates designed to tackle the root causes of these health issues, such as vascular inflammation, elevated cholesterol and triglyceride levels, and insulin resistance or diabetes. Notable candidates in their development pipeline include: VIA-3196: A liver-specific thyroid hormone receptor (THR) beta agonist, poised for Phase 1 clinical studies. This drug aims to mitigate dyslipidemia, addressing high LDL cholesterol, elevated triglycerides, and Lp(a) levels. A Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor: Currently in preclinical development for treating type 2 diabetes, with promising potential for weight management and other lipid disorders. VIA-2291: A 5-Lipoxygenase inhibitor that has successfully completed its third Phase 2 clinical trial. Its purpose is to target atherosclerotic plaque, a significant contributor to heart attacks, strokes, and various other vascular diseases. VIA Pharmaceuticals has also forged two research, development, and commercialization agreements with Hoffman-LaRoche Inc. and Hoffman-LaRoche Ltd. These collaborations pertain to their THR beta agonist program and several compounds from their preclinical DGAT1 metabolic disorders initiative. Established in 2004, the company's headquarters are located in San Francisco, California.
Részvényárfolyam
$0.0005
Utolsó szinkronizálás: 2026-08-11
Piaci kapitalizáció
$10.28K
Változás (1 nap)
0.00%
Változás (1 év)
0.00%
Ország
US
Kereskedés VIA Pharmaceuticals, Inc. (VIAP)

Kategória

Healthcare
VIA Pharmaceuticals, Inc. (VIAP) P/S aránya
P/S arány ekkor: 2026 TTM: 0
VIA Pharmaceuticals, Inc. legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi árbevétel aránya (P/S, TTM) 0. 2026 végén ez az arány 0 volt.
P/S arány története a(z) VIA Pharmaceuticals, Inc. esetén 2026 és 2026 között
P/S arány az év végén
Év P/S arány Változtassa meg
Nincs elég adat a megadott dátumokhoz.
P/S arány hasonló vállalatoknál vagy versenytársaknál
Vállalat P/S arány P/S arány különbség Ország
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
10.30 -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
- -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
- -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
- -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
14.90 -
US